Kotowicz Beata, Fuksiewicz Malgorzata, Jonska-Gmyrek Joanna, Berezowska Alicja, Radziszewski Jakub, Bidzinski Mariusz, Kowalska Maria
Laboratory of Tumor Markers, Department of Pathology and Laboratory Diagnostics, Maria Sklodowska - Curie Institute - Oncology Center, Warsaw, Poland.
Department of Urooncology, Maria Sklodowska - Curie Institute - Oncology Center, Warsaw, Poland.
PLoS One. 2017 Oct 9;12(10):e0184576. doi: 10.1371/journal.pone.0184576. eCollection 2017.
The study aimed to assess the usefulness of the determination of cytokines: IL-8, VEGF and its soluble receptors: VEGF-R1, VEGF-R2 in patients with endometrial cancer (EC).
MATERIAL/METHODS: The study group consisted of 118 patients with EC subjected to surgical treatment. Before the treatment we determined the serum levels of cytokines IL-8, and VEGF as well as VEGFR1 and VEGFR2 receptors. For comparison, the concentration of CA 125 was also measured. VEGFR1 and CA 125 were determined in the COBAS e601 system using Roche Diagnostics kits, while IL-8, VEGF and VEGFR2 were measured by ELISA assay using R&D Systems kits.
The concentrations of IL-8, VEGF, VEGFR1 and CA 125 allowed to distinguish patients for the control group. The highest diagnostic sensitivity has been shown for the concentrations of VEGF (AUC = 0.904) and IL-8 (AUC = 0.818). Among all studied parameters only CA125 concentrations increased with the clinical stage; being significantly higher in patients in FIGO III-IV, than FIGO I-IB. In patients at the FIGO stage I-IB, complementary determinations of CA 125 and VEGF resulted in the largest increase of diagnostic sensitivity. Patients with metastases to the para-aortic lymph nodes had significantly higher levels of VEGF compared to subjects without such lesions. The concentrations of IL-8 were an independent prognostic factor in the assessment of overall survival in patients with type I endometrial cancer, while the concentrations of VEGFR2 in those with type II.
In patients with endometrial cancer, the clinical usefulness of IL-8 and VEGFR2 measurements as the potential prognostic factors has been demonstrated. In type I, the concentrations of IL-8 determined before treatment can be helpful in predicting overall survival. In patients qualified to type II EC, the concentrations of VEGFR2 have the value of an independent prognostic factor for overall survival, this requires research on larger groups of patients. The increased levels of VEGF may be useful in the preoperative assessment of the status of para-aortic lymph nodes.
本研究旨在评估细胞因子白细胞介素-8(IL-8)、血管内皮生长因子(VEGF)及其可溶性受体VEGF-R1、VEGF-R2在子宫内膜癌(EC)患者中的检测价值。
材料/方法:研究组由118例行手术治疗的EC患者组成。治疗前测定血清中细胞因子IL-8、VEGF以及VEGFR1和VEGFR2受体水平。作为对照,同时检测CA 125浓度。VEGFR1和CA 125采用罗氏诊断试剂盒在COBAS e601系统中测定,而IL-8、VEGF和VEGFR2采用R&D Systems试剂盒通过酶联免疫吸附测定法(ELISA)检测。
IL-8、VEGF、VEGFR1和CA 125的浓度有助于区分对照组患者。VEGF(曲线下面积[AUC]=0.904)和IL-8(AUC=0.818)浓度显示出最高的诊断敏感性。在所有研究参数中,只有CA125浓度随临床分期增加;国际妇产科联盟(FIGO)III-IV期患者的CA125浓度显著高于FIGO I-IB期患者。在FIGO I-IB期患者中,联合检测CA 125和VEGF可使诊断敏感性提高最多。与无此类病变的患者相比,腹主动脉旁淋巴结转移患者的VEGF水平显著更高。IL-8浓度是评估I型子宫内膜癌患者总生存期的独立预后因素,而VEGFR2浓度则是II型患者的独立预后因素。
在子宫内膜癌患者中,已证实检测IL-8和VEGFR2作为潜在预后因素具有临床意义。在I型患者中,治疗前测定的IL-8浓度有助于预测总生存期。在符合II型EC的患者中,VEGFR2浓度对总生存期具有独立预后因素的价值,这需要对更大规模的患者群体进行研究。VEGF水平升高可能有助于术前评估腹主动脉旁淋巴结状态。